Results 61 to 70 of about 28,483 (297)
Mismatch-based delayed thrombolysis: a meta-analysis [PDF]
<p><b>Background and Purpose</b>: Clinical benefit from thrombolysis is reduced as stroke onset to treatment time increases. The use of "mismatch" imaging to identify patients for delayed treatment has face validity and has been used in
Anthony J. Furlan+6 more
core +1 more source
Introduction It is unknown whether alteplase is effective and safe in patients with mild acute ischemic stroke (AIS). Determining whether symptoms are “disabling” or not is a crucial factor in the management of these patients.
G. Merlino+11 more
semanticscholar +1 more source
Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis [PDF]
<p>Background and Purpose: Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been ...
Evelyn Teasdale+6 more
core +1 more source
The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt
IntroductionStroke is the second leading cause of mortality worldwide. Five percent of all the disability-adjusted life years (DALYs) lost around the world are attributed to stroke. This study aimed to assess the economic burden of acute ischemic stroke (
Hany Aref+5 more
doaj +1 more source
Background: Carotid tandem lesions ((TL) ⩾70% stenosis or occlusion) account for 15–20% of acute stroke with large vessel occlusion. Aims: We investigated the safety and efficacy of intravenous tenecteplase (0.25 mg/kg) versus intravenous alteplase (0.9 ...
F. Bala+34 more
semanticscholar +1 more source
Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial [PDF]
<p><b>Background and Purpose:</b> NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.
Ashwood, T.+11 more
core +1 more source
Background The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction
Nadinda A. M. van der Ende+17 more
doaj +1 more source
Alteplase as an Alternative to Urokinase
Abbreviations: DVT deep vein thrombosis, PAOD peripheral arterial occlusive disease, rt-PA recombinant tissue plasminogen activator, UK urokinase For the past 20 years, urokinase (UK) has been the primary agent used in the United States for catheter-directed thrombolytic therapy of acute limb ischemia and deep vein thrombosis (DVT), and for restoration
Karim A. Calis+9 more
openaire +2 more sources
Impact of Alteplase on Mortality in Critically Ill Patients with COVID-19 and Pulmonary Embolism
COVID-19 is an independent risk factor for pulmonary embolism (PE). Little is known about alteplase therapy in this patient group. A retrospective study analyzed 74 patients with PE and acute respiratory distress syndrome (ARDS) due to COVID-19 who were ...
O. Oliynyk+9 more
semanticscholar +1 more source
Thrombolysis and thrombectomy for acute ischaemic stroke [PDF]
The likelihood of disability-free recovery after acute ischemic stroke is significantly improved by reperfusion either by intravenous thrombolytic drug treatment or with endovascular mechanical thrombectomy in selected cases.
El Tawil, Salwa, Muir, Keith W.
core +1 more source